Metabolic effects of a growth hormone-releasing factor in patients with HIV.

Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S

The New England journal of medicine1 Dec 2007Cited by 139 (Europe PMC)

PMID18057338DOI10.1056/nejmoa072375PepBankPUB-18057338

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In HIV patients with abdominal fat, tesamorelin reduced visceral adipose tissue (VAT) versus placebo over 26 weeks.
In plain wordsIn HIV patients with belly fat, tesamorelin reduced belly organ fat while placebo patients had an increase.
Peptide
Tesamorelin
Outcome
DecreaseVAT percent change
Study
n = 412
Comparator
Placebo
Analysis
Primary
Outcome group
Body composition · Metabolic and weight
Studied dose
2 mg · subcutaneous · 26 weeksAs given in this study (human).
Measurements
VAT change
−15.2%
tesamorelin
VAT change
5%
placebo
Source sentences
Summary
The measure of visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat to receive a daily subcutaneous injection of either 2 mg of tesamorelin or placebo for 26 weeks.
Report a problemFND-1805733801
02HumanRandomized controlled trialEfficacy outcome
In HIV patients with abdominal fat, tesamorelin lowered triglycerides versus placebo.
In plain wordsIn HIV patients with belly fat, tesamorelin lowered triglycerides while placebo patients had an increase.
Peptide
Tesamorelin
Outcome
DecreaseTriglycerides change
Study
n = 412
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
2 mg · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Triglycerides change
−50 mg per deciliter
tesamorelin
Triglycerides change
9 mg per deciliter
placebo
Source sentences
Summary
the levels of triglycerides decreased by 50 mg per deciliter and increased by 9 mg per deciliter, respectively
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat to receive a daily subcutaneous injection of either 2 mg of tesamorelin or placebo for 26 weeks.
Report a problemFND-1805733802
03HumanRandomized controlled trialEfficacy outcome
In HIV patients with abdominal fat, tesamorelin lowered the ratio of total cholesterol to HDL cholesterol versus placebo.
In plain wordsIn HIV patients with belly fat, tesamorelin lowered the cholesterol to HDL ratio while placebo patients had an increase.
Peptide
Tesamorelin
Outcome
DecreaseTotal cholesterol to HDL cholesterol ratio change
Study
n = 412
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Metabolic and weight
Studied dose
2 mg · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Cholesterol/HDL ratio change
−0.31
tesamorelin
Cholesterol/HDL ratio change
0.21
placebo
Source sentences
Summary
the ratio of total cholesterol to HDL cholesterol decreased by 0.31 and increased by 0.21, respectively (P<0.001 for all comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat to receive a daily subcutaneous injection of either 2 mg of tesamorelin or placebo for 26 weeks.
Report a problemFND-1805733803
04HumanRandomized controlled trialEfficacy outcome
In HIV patients with abdominal fat, tesamorelin increased IGF-I versus placebo.
In plain wordsIn HIV patients with belly fat, tesamorelin raised IGF-I levels while placebo patients had a small decrease.
Peptide
Tesamorelin
Outcome
IncreaseIGF-I change
Study
n = 412
Comparator
Placebo
Analysis
Secondary
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
2 mg · subcutaneous · 26 weeksAs given in this study (human).
Measurements
IGF-I change
81%
tesamorelin
IGF-I change
−5%
placebo
Source sentences
Summary
Levels of IGF-I increased by 81.0% in the tesamorelin group and decreased by 5.0% in the placebo group (P<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat to receive a daily subcutaneous injection of either 2 mg of tesamorelin or placebo for 26 weeks.
Report a problemFND-1805733806
05HumanRandomized controlled trialEfficacy outcome
In HIV patients with abdominal fat, total cholesterol improved significantly in the tesamorelin group.
In plain wordsIn HIV patients with belly fat, total cholesterol improved significantly in the tesamorelin group.
Peptide
Tesamorelin
Outcome
Direction not reportedTotal cholesterol
Study
n = 412
Outcome group
Lipids · Metabolic and weight
Studied dose
2 mg · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Levels of total cholesterol and HDL cholesterol also improved significantly in the tesamorelin group.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat to receive a daily subcutaneous injection of either 2 mg of tesamorelin or placebo for 26 weeks.
Report a problemFND-1805733804
06HumanRandomized controlled trialEfficacy outcome
In HIV patients with abdominal fat, HDL cholesterol improved significantly in the tesamorelin group.
In plain wordsIn HIV patients with belly fat, HDL cholesterol improved significantly in the tesamorelin group.
Peptide
Tesamorelin
Outcome
Direction not reportedHDL cholesterol
Study
n = 412
Outcome group
Lipids · Metabolic and weight
Studied dose
2 mg · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Levels of total cholesterol and HDL cholesterol also improved significantly in the tesamorelin group.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat to receive a daily subcutaneous injection of either 2 mg of tesamorelin or placebo for 26 weeks.
Report a problemFND-1805733805
07HumanRandomized controlled trialSafety outcome
In HIV patients with abdominal fat, adverse events did not differ significantly between tesamorelin and placebo.
In plain wordsIn HIV patients with belly fat, side effects did not differ significantly between tesamorelin and placebo.
Peptide
Tesamorelin
Outcome
No significant changeAdverse events
Study
n = 412
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
2 mg · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Adverse events did not differ significantly between the two study groups
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat to receive a daily subcutaneous injection of either 2 mg of tesamorelin or placebo for 26 weeks.
Report a problemFND-1805733807
08HumanRandomized controlled trialSafety outcome
In HIV patients with abdominal fat, more patients withdrew because of an adverse event with tesamorelin than with placebo.
In plain wordsIn HIV patients with belly fat, more patients on tesamorelin than on placebo left the study because of a side effect.
Peptide
Tesamorelin
Outcome
IncreaseWithdrawal due to adverse event
Study
n = 412
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
2 mg · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
but more patients in the tesamorelin group withdrew from the study because of an adverse event.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat to receive a daily subcutaneous injection of either 2 mg of tesamorelin or placebo for 26 weeks.
Report a problemFND-1805733808
09HumanRandomized controlled trialSafety outcome
In HIV patients with abdominal fat, glycemic measures (glucose and insulin) did not differ significantly between groups.
In plain wordsIn HIV patients with belly fat, blood glucose and insulin did not differ significantly between tesamorelin and placebo.
Peptide
Tesamorelin
Outcome
No significant changeGlycemic measures
Study
n = 412
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were observed in glycemic measures.
1 context sentence(design, population, supporting numbers)
Summary · context
We randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat to receive a daily subcutaneous injection of either 2 mg of tesamorelin or placebo for 26 weeks.
Report a problemFND-1805733809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00123253

TH9507 in Patients With HIV-Associated Lipodystrophy

Theratechnologiesn = 412Jun 2005 to Apr 2007

HIV Infections · Lipodystrophy

Trial page ClinicalTrials.govUpdated 27 Nov 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.